NEOVAXSYN INC
NEOVAXSYN INC is a federal contractor, registered under UEI EHMTBALCKFE8 and CAGE code 7RK00. It has been awarded $4,551,873 in federal contracts. Primary work spans Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) and Unknown NAICS. Top awarding agencies include Department Of Health And Human Services.
Contact Information
Registration and classification details
Registration
UEI Code
EHMTBALCKFE8CAGE Code
7RK00Entity Structure
Corporate Entity (Not Tax Exempt)Established
N/ABusiness Classifications
NAICS Codes
Federal Contracting Overview
Award totals, agency breakdown, NAICS distribution, and geographic footprint.
AI Capability Profile
NEOVAXSYN INC specializes in the design and development of next-generation immunopreventive platforms targeting complex viral pathogens, with a focused expertise in nanovaccine engineering and broadly neutralizing antibody (bnAb) induction against HIV-1. The company leverages advanced antigen design...
NEOVAXSYN INC specializes in the design and development of next-generation immunopreventive platforms targeting complex viral pathogens, with a focused expertise in nanovaccine engineering and broadly neutralizing antibody (bnAb) induction against HIV-1. The company leverages advanced antigen design, nanoparticle delivery systems, and structural immunology to engineer precision immunogens capable of eliciting durable, cross-reactive humoral responses. Their technical proficiency spans rational vaccine design, epitope mapping, and immunogen optimization for difficult-to-target conserved regions of viral envelopes, positioning them at the forefront of HIV vaccine innovation. Key differentiators include their ability to translate computational immunology insights into clinically viable nanoscale formulations and their iterative, data-driven approach to overcoming immune evasion mechanisms inherent in HIV. The contractor maintains a consistent and deep engagement with the Department of Health and Human Services, delivering high-impact research and development solutions primarily through SBIR and direct R&D contracts. Their work for HHS centers on translational vaccine development, bridging early-stage discovery with preclinical validation, and aligning closely with NIH and CDC priorities in infectious disease prevention. NEOVAXSYN INC’s primary industry focus is in Research and Development in the Physical, Engineering, and Life Sciences (NAICS 541715), where they operate as a niche biotech innovator specializing in infectious disease immunology and nanomedicine. Their market positioning is defined by cutting-edge vaccine platforms that address persistent global health challenges, particularly those requiring novel immune activation strategies beyond conventional approaches. As a small business structured as a 2L entity based in Ames, Iowa, NEOVAXSYN INC operates with agility and scientific rigor, focusing exclusively on federally funded R&D initiatives. While currently holding no formal government certifications, their consistent award history with HHS underscores their credibility and technical competence within the federal biomedical research ecosystem.
Key Performance Metrics
Awards Count
8
All time
Active
2
Currently performing
Completed
6
Past period of performance
Total Awards
All time
Contracts
Prime · all time
Subcontracts
Sub · all time
Grants
Prime · all time
Subgrants
Sub · all time
Award Analytics & Distribution
Compete with NEOVAXSYN INC
Track the contractors you bid against, and the work they win
Award history, agency mix, and NAICS coverage for NEOVAXSYN INC
AI-powered matching against your own capabilities and past performance
Teaming and subcontracting signals on every award
Automated alerts when a competitor wins in your market
Join 750+ contractors already using CLEATUS
